H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on ImmunoGen to $28 from $27 and keeps a Buy rating on the shares post the Q3 report. The analyst says increased adoption and geographic expansion will drive Elahere growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMGN: